Calyon was appointed as one of the 4 Bookrunners of a EUR 8 bn revolving credit facility on behalf of the French drug maker Sanofi-Aventis. The deal consists of a EUR 5.5 billion 5+1+1year tranche and a EUR 2.5 billion straight 7-year tranche. The transaction was oversubscribed. This new mandate confirms Calyon's leading role with Sanofi-Aventis. Sanofi-Aventis is the world's third-largest company in the pharmaceutical industry.